Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is characterised by irreversible airflow limitation associated with chronic inflammation. Matrix metalloproteinases (MMPs) are proteolytic enzymes that contribute to the inflammatory response in COPD and degrade extracellular matrix components. Their enzy...

Full description

Saved in:
Bibliographic Details
Published in:Archivum Immunologiae et Therapiae Experimentalis 2016-06, Vol.64 (3), p.177-193
Main Authors: Navratilova, Zdenka, Kolek, Vitezslav, Petrek, Martin
Format: Article
Language:English
Subjects:
Biomarkers - metabolism
Biomedical and Life Sciences
Biomedicine
Cross-Sectional Studies
Gene Expression Regulation, Enzymologic
Humans
Immunology
Inflammation
Lung - metabolism
Matrix Metalloproteinase 9 - metabolism
Matrix Metalloproteinases - metabolism
MicroRNAs - metabolism
Pharmacology/Toxicology
Phenotype
Prognosis
Pulmonary Disease, Chronic Obstructive - enzymology
Review
Tissue Inhibitor of Metalloproteinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic obstructive pulmonary disease (COPD) is characterised by irreversible airflow limitation associated with chronic inflammation. Matrix metalloproteinases (MMPs) are proteolytic enzymes that contribute to the inflammatory response in COPD and degrade extracellular matrix components. Their enzymatic activity is inhibited by a four-member family of tissue inhibitors of metalloproteinases (TIMPs). In COPD, the MMP/TIMP network, mainly MMP-9, has been repeatedly observed to be dysregulated at both the local (lung) and systemic levels. Here, we review the findings reported in numerous cross-sectional studies with our primary focus on longitudinal observations in human COPD studies. The data from longitudinal prospective studies on the MMP/TIMP network may lead to the introduction of novel prognostic biomarkers into clinical management of COPD. We address the relationship between the systemic and local lung MMP/TIMP network in COPD patients and briefly describe the involvement of microRNAs. Finally, the role of the MMP/TIMP network in COPD treatment is discussed.
ISSN:0004-069X
1661-4917
DOI:10.1007/s00005-015-0375-5